Qmb
2 known investors
QualiVerse is an AI-native regulatory intelligence platform that automates FDA submission documentation and compliance workflows for medical device companies. It uses generative AI combined with expert review to identify regulatory risks, determine product classification, and accelerate time-to-market for medtech innovators.
Also known as QMB, Inc. · QMB, LLC · Quality Means Business · QualiVerse
Investors · 2
Also in the syndicate · 1
Company profile
researched Aug 2026Quality Means Business (QMB, Inc.), operating at qmb.ai, is a Boston, Massachusetts-based company that develops AI-driven software and advisory services for medical device (MedTech) quality, regulatory affairs, and new product development. Its flagship product, QualiVerse®, is described as a regulatory intelligence engine that unifies design control, risk management, regulatory intelligence, and compliance scoring in a single enterprise system, using generative AI together with expert oversight to automate device classification, identify predicate devices, generate submission-ready documentation, flag risks, and simulate FDA-ready submissions.
Alongside the platform, QMB offers strategic regulatory services (regulatory strategy, QMS deployment, and new product submissions) and quality and clinical advisory work covering clinical trial management, verification and validation, eQMS transitions, and post-market readiness. The company positions the platform against standards including FDA requirements, ISO 13485, ISO 14971, IEC 62304, and EU MDR, converting them into workflow-aware processes, and markets a proprietary seven-point AI risk model for audit readiness. QMB describes its approach as "RegTech-as-Infrastructure™" and an "expert-in-the-loop" model in which regulatory specialists validate AI-generated outputs.
Founding story
Founder Michel E. Moravia began his career in biochemical sciences, working at Novartis on upstream DNA assessment, optimization, and quantification for a companion diagnostic assay for Fragile X Syndrome, where he concluded that quality functions mirror the safety and public-health goals of the FDA and other regulators. He subsequently held quality roles at SCIEX (a Danaher company), earned dual master's degrees at Boston University in product design and manufacturing engineering and an MBA with a health sector management concentration, and worked as a product leader at electronic quality management system software vendors before launching Quality Means Business to address gaps he saw in the industry.
Business model
Vertical SaaS platform (QualiVerse®) sold to MedTech companies, augmented by embedded expert services in regulatory strategy, quality management system deployment, and clinical/quality advisory. The company describes enterprise pilots with MedTech manufacturers as a route to adoption.
Traction
The company cites pilot interest and early enterprise traction with medical device companies, with RegTech-as-Infrastructure™ pilots planned to begin in late 2025. Website claims include a 95% submission success rate and 80% faster submission preparation time, and a customer testimonial from the CEO of GuideAIHealth describes accelerated product code selection, predicate device identification, and design planning documentation for an FDA pre-submission.
Latest developments
In November 2025, QMB announced a $2 million seed round led by The Boston Foundation's Business Equity Investment Fund and CEI Ventures, to be used to expand engineering, deepen data integrations, and advance RegTech-as-Infrastructure™ pilots with MedTech manufacturers beginning in late 2025. The company's governance was reported to include Michel Moravia as Chairman and CEO, Orlando Watkins (The Boston Foundation) and Robert Bennett as board directors, and Shannon Bean of CEI Ventures as board observer.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positions itself as an emerging AI-driven MedTech SaaS provider and, per investor commentary, as a category-defining company at the intersection of AI, regulatory intelligence, and medical technology, aiming to replace manual regulatory workflows with integrated software infrastructure.
Combines automated, AI-generated regulatory documentation with an expert-in-the-loop review model staffed by regulatory professionals; unifies design control, risk management, regulatory intelligence, and compliance scoring in one system rather than separate tools; and embeds multiple global standards frameworks into a single workflow.
Technology
QualiVerse® is described as an AI-native engine combining generative AI, AI copilots, predictive analytics, and compliance-aware automation with human expert review. Stated capabilities include automated product classification, predicate device identification, generation of large volumes of submission-ready documentation benchmarked against real-world FDA data, a proprietary seven-point AI risk model, compliance scoring, and alignment with FDA, EU MDR, ISO 13485, ISO 14971, and IEC 62304 requirements.
Go-to-market
Direct enterprise sales supported by demo requests on the company website, customer testimonials from MedTech clients, and pilot programs with medical device manufacturers. The leadership team includes a VP of Sales focused on medical device, digital health, and AI platform sales, and a marketing director focused on go-to-market and demand generation.
Medical device and life sciences companies, including MedTech startups and founders, regulatory affairs and quality assurance teams, and established medical device manufacturers pursuing FDA submissions and global market clearances.
Geography
Headquartered in Boston, Massachusetts, United States, with a platform designed for global regulatory regimes including the United States (FDA) and the European Union (EU MDR).
History
QMB was founded by Michel E. Moravia, initially as QMB, LLC, a quality consultancy with proprietary technology serving the medical device industry. In 2020, when the company was at an early stage, an application to the MassChallenge Health accelerator was rejected; Moravia later carried out an organizational restructuring that included hiring new technical talent and halving C-suite guaranteed payments to reinvest in product development. The company subsequently developed and launched the QualiVerse® platform, and in November 2025 announced a $2 million seed round to support the launch.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsQuality Means Business (QMB, Inc.) announced a $2 million seed round led by The Boston Foundation's Business Equity Investment Fund and CEI Ventures, to fund engineering expansion, data integrations, and RegTech-as-Infrastructure pilots with MedTech manufacturers.
$2M source ↗
QMB's governance was reported as Michel Moravia (Chairman & CEO), Orlando Watkins of The Boston Foundation (board director), Robert Bennett (board director), and Shannon Bean of CEI Ventures (board observer).
QMB launched QualiVerse, a regulatory intelligence engine unifying design control, risk management, regulatory intelligence, and compliance scoring for medical device innovators.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Qmbqmb.ai · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Qmb do?
- QMB builds QualiVerse, an AI-native regulatory intelligence and compliance platform for medical device companies.
- Who are Qmb's investors?
- Qmb's investors include CEI Ventures.